Physicians' Academy for Cardiovascular Education

Hypertension

No clinical benefit from suspending ACEi/ARBs in hospitalized patients with COVID-19

3' education - Sep. 7, 2020 - Prof. Renato D. Lopes, MD, PhD

BP lowering should be considered irrespective of prior CVD or baseline SBP

3' education - Sep. 1, 2020 - Kazem Rahimi, MD
Lecture 1 out of 3

COVID-19, ACE2 and RAASi - a scientific perspective

10' education - Apr. 19, 2020 - Prof. Jan Danser, PhD
Lecture 2 out of 3

A clinical perspective on COVID-19, ACE2 and RAAS inhibition

10' education - Apr. 18, 2020 - Prof. Murray Epstein, MD

Biochemical urine test to measure medical adherence in hypertension

5' education - Oct. 24, 2019 - Paris, France - Dan Lane

Decreased CV risk with an intervention targeting identified barriers to care

3' education - Aug. 31, 2019 - ESC 2019, Paris - Prof. J-D Schwalm

Community-wide salt restriction reduces blood pressure and incidence of hypertension

3' education - Sep. 2, 2019 - Paris, France - Prof. Jaime Miranda

RAAS inhibition in patients with kidney disease: Balancing the benefits and risks

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. Patrick Rossignol, MD - Online CME

New recommendations of the ESC/ESH Guidelines on the management of hypertension

3' education - Feb. 11, 2019 - Prof. Bryan Williams - London, UK

Get involved in May Measurement Month to increase awareness of elevated blood pressure

3' education - Feb. 6, 2019 - Prof. Neil Poulter - London, UK

Long term benefits of antihypertensive and cholesterol-lowering treatment in hypertension

10' education - Nov. 20, 2018 - Dr. Ajay Gupta - London, UK

Screening for high blood pressure globally

10' education - Nov. 20, 2018 - Dr. Thomas Beaney - London, Uk

Importance of hypertension in CVD prevention

10' education - June 12, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (1/3)

The cardiovascular challenge for primary care in diabetes

10' education - June 14, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME

The future of renal denervation in the treatment of hypertension

3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Michael Böhm, Homburg, Germany

Pharmacist intervention in black barbershop beats usual care at lowering BP

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Dr. Ronald Victor, MD - Los Angeles, CA, USA

New ACC/AHA hypertension guidelines empasize risk assessment

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Prof. Clyde Yancy - Chicago, IL, USA

Good BP measurement depends more on appropriate technique than on absence of staff

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Karen Johnson - Memphis, TN, USA

Target for BP lowering differs between Europe and USA

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Prof. Clyde Yancy - Chicago, IL, USA

Clinical outcomes and adverse effects comparable across various BP measurement methods in SPRINT

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Dr. Sripal Bangalore - NYU Langone, New York, NY, USA.

New ACC/AHA Hypertension Guidelines: stress on accuracy BP measurement method and lifestyle changes ánd a new target

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Paul Whelton, MD (Tulane University, New Orleans, LA, USA

BP lowering with endovascular baroreflex amplification in resistant hypertension: the CALM-FIM study

3' education - Aug. 29, 2017 - Dr. Wilko Spiering - UMCU

Take home messages of the ESC congress for better hypertension treatment

3' education - Aug. 29, 2017 - Dr. Clyde Jancy - Northwestern University, Feinberg University, Chicago, IL, VS

Well-conducted trial confirms principle that renal denervation can lower blood pressure

3' education - Aug. 29, 2017

NSAID ibuprofen increases blood pressure significantly more than other selective COX2 inhibitors

3' education - Aug. 28, 2017

E-counselling improves adherence in hypertensives

3' education - Mar. 21, 2017 - Dr. Rob Nolan, Toronto, ONT, Canada

Get involved in May Measurement Month!

3' education - Jan. 22, 2017 - London, United Kingdom - Prof. Neil R Poulter, MD (London, UK) - ISH President

How low to go with blood pressure: J-curve or not?

3' education - Nov. 12, 2016 - New Orleans, LA, USA - Deepak L.Bhatt, MD, MPH (Boston, MA, USA)

To SPRINT or not to SPRINT to a lower blood pressure target?

10' education - Aug. 29, 2016 - ESC Rome, Italy - William C Cushman (Memphis, TN, USA) and Sverre E Kjeldsen (Oslo, Norway)
##SCROLLER_ITEMS_FULL_TITLE##

BP-lowering medication should not be used in normotensive primary prevention population at intermediate CV risk

10' education - May 10, 2016 - ACC 2016, Chicago, IL, USA - Eva Lonn (Hamilton, ONT, Canada)

Moderate and heavy alcohol consumption associated with hypertension

Literature - Sep. 28, 2020 - Mayl JJ et al. - J Am Heart Assoc. 2020

Compared to those who reported no alcohol intake, T2DM patients with moderate (>7 drinks/week) and heavy (>14 drinks/week) alcohol consumption had increased risk of elevated BP, hypertension grade I and hypertension grade 2.

No clinical benefit from suspending ACEi/ARBs in hospitalized patients with COVID-19

3' education - Sep. 7, 2020 - Prof. Renato D. Lopes, MD, PhD
BRACE CORONA was a randomized trial that tested two strategies in hospitalized patients with COVID-19 who were on ACEi or ARBs: Temporarily suspending or continuing ACEi/ARBs. Prof. Lopes discusses the results.

ESC 2020 BRACE CORONA was a randomized trial that tested two strategies in hospitalized patients with COVID-19 who were on ACEi or ARBs: Temporarily suspending or continuing ACEi/ARBs. Prof. Lopes discusses the results.

BP lowering should be considered irrespective of prior CVD or baseline SBP

3' education - Sep. 1, 2020 - Kazem Rahimi, MD
BP lowering  of 5 mm Hg results in 10% reduction of major CV events and is consistent whether individuals had a previous CVD or not, and is regardless of baseline SBP.

ESC 2020 A study including 48 RCTs demonstrated that lowering of each 5 mmHg SBP resulted in 10% reduction of major CV events, regardless of baseline SBP and CVD status.

Lowering BP reduces risk of major CV events regardless of CVD status and baseline SBP

News - Sep. 1, 2020

ESC 2020 Blood pressure-lowering reduces the risk of major CV events similarly in those with and without CVD and irrespectively of baseline SBP.

Randomized trial on continuing versus suspending ACEi and ARBs in COVID-19

News - Sep. 1, 2020

ESC 2020 Suspension of ACEi/ARB therapy for 30 days did not impact the number of days alive and out of hospital at 30 days compared to continued use of these medications in COVID-19 patients.

Risk of ASCVD gradually increases with increasing SBP levels starting from 90 mmHg

Literature - July 6, 2020 - Whelton SP et al. - JAMA Cardiol. 2020.

Presence of coronary artery calcium and risk of incident ASCVD events increased with increasing SBP levels in individuals with a SBP between 90 and 129 mmHg and no other traditional ASCVD risk factors.

Similar BP reductions after renal denervation across high-risk subgroups and ASCVD risk scores

Literature - June 25, 2020 - Mahfoud F et al., - J Am Coll Cardiol. 2020.

This post-hoc analysis demonstrated similar BP reductions after renal denervation (RDN) across high-risk subgroups and ASCVD risk scores. Reductions were sustained up to 3 years after RDN.

Earlier onset of hypertension associated with higher risk for mortality

Literature - June 23, 2020 - Wang C et al., - J Am Coll Cardiol. 2020.

In a case-control study of Chinese adults divided in age groups, earlier onset of hypertension was associated with higher risk of all-cause mortality and a trend for higher risk of CVD.

Antihypertensive medication reduction noninferior to usual care in elderly patients

Literature - June 9, 2020 - Sheppard JP, et al. - JAMA 2020

Reduction of antihypertensive medication in patients ≥80 years who were on ≥2 antihypertensive medication was noninferior to usual care with regard to SBP control at 12 weeks.

Three studies show no harm of ARBs/ACEi in COVID-19 patients

News - May 26, 2020

Recently, three papers were published in the N Engl J Med on the effect of ACE inhibitors and ARBs in patients with COVID-19. All three studies showed no evidence that ACE inhibitors or ARBs affect the risk of COVID-19.

Trial started with SGLT2i in COVID-19

News - May 4, 2020
A randomized, phase 3 trial, called DARE-19, evaluates the effect of dapagliflozin on disease progression, clinical complications and mortality in patients hospitalized with COVID-19, who also have CV, metabolic or kidney risk factor.

A randomized, phase 3 trial, called DARE-19, evaluates the effect of dapagliflozin on disease progression, clinical complications and mortality in patients hospitalized with COVID-19, who also have CV, metabolic or kidney risk factor.

COVID-19, ACE2 and RAASi - a scientific perspective

10' education - Apr. 19, 2020 - Prof. Jan Danser, PhD
This presentation is part of a webinar on COVID-19, ACE2 and RAAS inhibition and focusses on the scientific data that is available on the ACE2 receptor and RAAS inhibitors.

This presentation is part of a webinar on COVID-19, ACE2 and RAAS inhibition and focusses on scientific data that is available on the ACE2 receptor and RAAS inhibitors.